Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Alto Neuroscience (ANRO) EPS (Basic) (2023 - 2026)

Alto Neuroscience has reported EPS (Basic) over the past 4 years, most recently at -$0.8 for Q1 2026.

  • Quarterly results put EPS (Basic) at -$0.8 for Q1 2026, down 42.86% from a year ago — trailing twelve months through Mar 2026 was -$2.42 (down 3.42% YoY), and the annual figure for FY2025 was -$2.19, up 12.4%.
  • EPS (Basic) reached -$0.8 in Q1 2026 per ANRO's latest filing, down from -$0.45 in the prior quarter.
  • Across five years, EPS (Basic) topped out at -$0.45 in Q4 2025 and bottomed at -$2.98 in Q4 2023.
  • Median EPS (Basic) over the past 4 years was -$0.65 (2025), compared with a mean of -$1.17.
  • The largest annual shift saw EPS (Basic) skyrocketed 81.21% in 2024 before it plummeted 42.86% in 2026.
  • Over 4 years, EPS (Basic) stood at -$2.98 in 2023, then surged by 81.21% to -$0.56 in 2024, then grew by 19.64% to -$0.45 in 2025, then crashed by 77.78% to -$0.8 in 2026.
  • Business Quant data shows EPS (Basic) for ANRO at -$0.8 in Q1 2026, -$0.45 in Q4 2025, and -$0.52 in Q3 2025.